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Abstract: Cervical metaplastic squamous epithelium exhibiting atypia insufﬁ  cient for a diagnosis of cervical intraepithelial 
neoplasia (CIN) is usually reported as “atypical squamous metaplasia” (ASM). Stratiﬁ  cation impacts treatment since the 
differential is often between reactive and high grade CIN (CIN II, III). Diagnosis with H&E is associated with low intra/
interobserver concurrence. P16/Ki-67 immunostains are helpful to assess cervical biopsies for HPV-associated lesions but 
staining in metaplastic squamous epithelium has received little attention. This study aims to establish staining characteristics 
of metaplastic squamous epithelium and determine if p16/Ki-67 is useful in ASM stratiﬁ  cation. 80 cervical biopsies containing 
morphologically normal and dysplastic squamous metaplasia were retrieved to determine the staining characteristics of 
metaplastic epithelium utilizing p16/Ki-67 immunostains. These included 21 benign squamous metaplasia (BSM) from 
benign cervices, 15 BSM present adjacent to HPV/CIN lesions, and 44 CIN involving squamous metaplasia. Serial sections 
with controls were stained for p16 and Ki-67 and in-situ hybridization (ISH) for low-risk (LR) and high-risk (HR) HPV 
was performed. P16 was recorded as negative, spotty, or band-like. Ki-67 was recorded as positive when present in  50% 
of lesional nuclei. Results were correlated with H&E diagnosis. 95% of the BSMs, whether from normal cervices or adjacent 
to HPV/CIN were p16/Ki-67 negative. 81% HG CINs involving squamous metaplasia were p16 band/Ki-67 positive. Low 
grade CIN (CIN I) involving metaplastic epithelium showed a broad distribution of p16/Ki-67 staining patterns. Based on 
these criteria, 20 ASM were evaluated. 10% of the ASM cases were p16 band/Ki-67 positive indicating HG CIN. 60% of 
the ASMs were p16/Ki-67 negative indicating reactive change (all with the exception of one case being HPV negative). The 
remaining 30% of the ASM cases showed variable positivity for p16 and Ki-67 and could not be stratiﬁ  ed into the two 
categories. Thus p16/Ki-67 staining is helpful in stratiﬁ  cation of ASM as reactive or CIN.
Keywords: P16, Ki-67, cervical intraepithelial neoplasia (CIN), human papilloma virus (HPV), atypical squamous 
metaplasia
Introduction
Cervical metaplastic squamous epithelium exhibiting atypia insufﬁ  cient for a diagnosis of cervical 
intraepithelial neoplasia (CIN) is usually reported as “atypical squamous metaplasia” (ASM). Stratiﬁ  cation 
of ASM into reactive and CIN groups impacts treatment since the differential is often between reactive 
and high (rather than low) grade CIN. Small biopsies, suboptimal orientation of sections, coexistent 
inﬂ  ammatory/reactive cellular changes, and subjective criteria contribute to low levels of intra- and 
inter-observer concurrence when the diagnosis of ASM is based on H&E stains alone. Adjuncts that 
could help stratify ASM would be helpful in patient management.
It has been shown that p16/Ki-67 immunostains are helpful in the assessment of cervical (Sano 
et al. 1998; Keating et al. 2001; Klaes et al. 2001; Agoff et al. 2003; Hu et al. 2005; O’Neill and 
McCluggage, 2006) and anal (Walts et al. 2006) biopsies for human papillomavirus (HPV)-associated 
lesions but staining in squamous metaplasia has received little attention to date (Keating et al. 2001; 
Duggan et al. 2006; Iaconis et al. 2007; Kong et al. 2007; Regauer and Rich, 2007). Brieﬂ  y, p16 is a 
cyclin-dependent kinase inhibitor that regulates transition from the G1 to the S phase of the cell cycle 
(Ortega et al. 2002). P16 has been shown to be upregulated and overexpressed in most high grade 
cervical dysplasias and carcinomas induced by high-risk (HR) HPV subtypes (Sano et al. 1998; Klaes 
et al. 2001). Ki-67 is a cell proliferation marker that is expressed during all phases of the cell cycle 
except G0 (Indinnimeo et al. 2000). This study was designed to establish baseline staining characteristics 
in squamous metaplastic epithelium so as to determine if p16/Ki-67 immunostaining is useful in 
stratiﬁ  cation of ASM.36
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Materials and Methods
The study was performed in two parts. The ﬁ  rst 
part was designed to determine the p16/Ki-67 
staining characteristics of morphologically normal 
and dysplastic metaplastic epithelium so as to 
develop algorithms for application to ASM. In the 
second portion of the study these algorithms were 
tested on a set of consecutive cases that had been 
reported as ASM in order to determine if it were 
possible to stratify cases of ASM into dysplastic 
or reactive groups.
After IRB approval, slides of 80 formalin ﬁ  xed 
parafﬁ  n embedded cervical biopsies were retrieved 
from our ﬁ  les and divided into three groups based 
on examination of routine H&E stained sections: 
(i) Benign squamous metaplasia (BSM) without 
morphologic evidence of HPV infection or CIN 
obtained from benign cervices (21 cases) (ii) unin-
volved (benign) squamous metaplasia adjacent to 
areas with evidence of HPV infection or CIN 
(15 cases) (iii) metaplastic epithelium involved by 
HPV or CIN (44 cases). All diagnoses had been 
rendered by experienced gynecologic pathologists 
and all were conﬁ  rmed by the authors (AW, SB) 
on slide review. Cases with discrepant diagnoses 
were excluded from the study. No additional exclu-
sion criteria were applied in case selection. For the 
second portion of the study 20 consecutive cases 
of ASM were retrieved from the ﬁ  les. These cases 
had also been reported by the same experienced 
gynecologic pathologists. An additional 10 ecto-
cervical biopsies with HPV and/or CIN were 
evaluated as controls. The specimens had been 
collected from 84 women ranging in age from 
10 to 71 years (mean 36.6 yrs; median 32.5 yrs).
Serial sections of the retrieved slides and appro-
priate controls were immunostained for p16 (Clone 
JC8 at dilution of 1:200 from Biocare Medical, 
Concord CA) utilizing Envision Plus Mouse Detec-
tion (DAKO, Carpinteria CA) and a DAKO Auto-
stainer and for Ki-67 (CONFIRM Anti-Ki67 (k-2) 
primary antibody from and as diluted by Ventana 
Medical Systems, Inc. Tucson, AZ). As positive 
controls for p16 and Ki-67 immunostains we uti-
lized paraffin sections of a HR HPV positive 
squamous carcinoma and of a tonsil, respectively. 
Sections of the cervical biopsies run substituting 
mouse IgG for p16 and Ki-67 antibody served as 
negative controls. Slides were treated with 3% 
hydrogen peroxide to block endogenous staining 
and the Envision polymer-based system was 
utilized for antigen detection. P16 antigen retrieval 
was accomplished by 30 minute incubation with 
steam and low pH buffer and Ki-67 antigen 
retrieval was accomplished by pretreatment on the 
Ventana Benchmark using CC1 buffer. The chro-
magen for both antibodies was DAB (3,3’-diami-
nobenzidene). P16 was recorded as negative 
(staining in 0%–25% of lesional cells), spotty 
(positive in  25% of cells distributed throughout 
the lesion, or band-like (positive in  90% of con-
tiguous lesional cells). Nuclear and/or both nuclear 
and cytoplasmic staining was interpreted as posi-
tive for p16; cytoplasmic staining alone was 
considered nonspeciﬁ  c and recorded as negative. 
Ki-67 was recorded as positive when present 
in  50% of lesional cell nuclei. Positive staining 
for Ki-67 was exclusively nuclear.
Serial sections of 88 (88%) of the biopsies 
(14 BSM, 12 BSM adjacent to CIN, 43 CIN in 
squamous metaplasia, 19 ASM) and 10 (100%) of 
the ectocervical controls were subjected to in-situ 
hybridization (ISH) for high risk (HR) HPV 
utilizing HPV-III Family 16 (Ventana). Serial 
sections of 93 (93%) of the biopsies (15 BSM, 15 
BSM adjacent to CIN, 44 CIN in squamous 
metaplasia, 19 ASM and 10 (100%) of the 
ectocervical controls were also subjected to in-situ 
hybridization for low risk (LR) HPV utilizing 
Inform HPV II-Family 6 and as per the 
manufacturer’s recommendations. Presence of LR 
and HR HPV was determined without knowledge 
of the p16/Ki-67 staining.
Immunostaining, ISH, and H&E diagnoses were 
correlated. Statistical analyses were performed 
using the Fisher exact test. A 2-sided p value of 
 0.05 was considered signiﬁ  cant.
Followup was available for 10 (50%) of the 
ASMs up to 19 months after the index samples had 
been obtained.
Results
BSM from morphologically normal cervices and 
BSM adjacent to HPV/CIN showed similar stain-
ing and were negative for p16 and Ki-67 (Table 1). 
Only two BSMs from morphologically normal 
cervices showed spotty p16 staining in 25%–50% 
of metaplastic cells and both of these were Ki-67/
HR and LR HPV negative. HPV (LR and/or HR) 
ISH was negative in all of the 33 (100%) BSMs 
that were tested.
CINs involving metaplastic epithelium showed 
staining similar to CIN in ectocervical epithelium. 37
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Band-like p16 immunostaining and Ki-67 positivity 
were present in 22 of 27 (81.5%) HG CINs involving 
metaplastic epithelium. Four of the remaining 5 HG 
CINs involving metaplastic epithelium showed p16 
positivity (2 band and 2 spotty  75%) of which 2 
were Ki-67/HR HPV DNA positive, one was Ki-67/
HPV DNA negative, and one was Ki-67 negative/
HR HPV DNA positive. The ﬁ  fth case (reported as 
CIN II) was p16/Ki-67/HPV negative. LG CIN 
involving metaplastic epithelium showed a broad 
distribution of p16/Ki-67 immunostaining patterns 
ranging from negative to positive.
Of the 10 ectocervical control cases, four were 
benign reactive ectocervical biopsies and all were 
p16/Ki-67/HPV negative, two were HG CIN and 
were p16 band/Ki-67 positive, one of which was 
also HR HPV ISH positive. Four were LG CIN 
and showed variable staining for p16 and Ki-67; 
two were positive for LR HPV, one was positive 
for HR HPV, and one was positive for both LR and 
HR HPV by ISH.
Thus to summarize, irrespective of the presence 
of adjacent HPV/CIN, morphologically normal and 
dysplastic lesions in metaplastic epithelium show 
a similar staining pattern to that seen in normal and 
dysplastic ectocervical epithelium, respectively. 
HG CIN is p16 band/Ki-67 positive, LG CIN shows 
a variable staining pattern, and benign squamous/
metaplastic epithelium is p16/Ki-67 negative.
Based on the above staining patterns, cases with 
ASM could be further stratiﬁ  ed into CIN and 
benign groups (Figs. 1–3). Of the 20 ASMs, 5 were 
p16 band positive; of these 4 were HR HPV posi-
tive while only 2 were Ki-67 positive. Fourteen 
(70%) ASMs were p16 negative; of these 13 were 
HPV negative with 11 also being Ki-67 negative. 
One ASM showed spotty p16 staining in 25%–50% 
of lesional cells; this biopsy was Ki-67 negative 
but HPV ISH was not done. Only one of the ASMs 
that were p16/Ki-67 negative was HR HPV ISH 
positive. Thus 14 (70%) of the ASMs (Table 1) 
could be reclassiﬁ  ed, 2 (10%) as HG CIN and 12 
(60%) as reactive changes.
Table 2 summarizes the p16 staining patterns 
in relation to H&E diagnosis and HPV ISH. Of the 
33 p16 band-positive cases, 25 (76%) were HR 
HPV positive while 8 cases were negative. These 
included 5 HG CIN cases with positive Ki-67 and 
Table 1. P16, Ki-67, and HPV staining in squamous metaplastic epithelium (N = 100).
p16 0%–25% 0%–25% 25%–75% 25%–75%  75%  75% Band Band
Ki-67  50%  50%  50%  50%  50%  50%  50%  50%
BSM in morphologically normal cervices (21 cases)
HPV− 90 2 0 00 0 0
LR−/HRND 40 0 0 00 0 0
HR−/LRND 30 0 0 00 0 0
HPV ND 3 0 0 0 0 0 0 0
BSM adjacent to CIN (15 cases)
HPV− 12 0 0 0 0 0 0 0
LR−/HRND 30 0 0 00 0 0
CIN in Metaplasia (44 cases)
LG CIN (17)
HPV− 40 1 0 00 1 0
LR+/HRND 1 0 0 0 0 0 0 0
LR−/HR+ 32 0 1 01 1 2
HG CIN (27 cases)
HPV− 10 0 0 00 1 5
LR−/HR+ 00 0 0 02 1 1 7
ASM (20 cases)
HPV− 11 2 0 0 0 0 1 0
LR−/HR+ 10 0 0 00 2 2
HPV ND 0 0 1 0 0 0 0 0
Abbreviations: LR−, ISH negative for LR HPV; HR−, ISH negative for HR HPV; LR+, ISH positive for LR HPV; HR+, ISH positive for HR 
HPV; LRND, ISH for LR HPV not done; HRND, ISH for HR HPV not done; HPV ND, ISH for HPV not done.38
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Figures 1 and 2. (a) Atypical squamous metaplasia with (b) band-like p16 staining, (c) positive Ki-67, and (d) positive HR HPV on ISH 
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1 LG CIN, 1 ASM, and 1 HG CIN each with 
negative Ki-67. All of the three cases with spotty 
p16 positivity in  75% and Ki-67 positivity in 
 50% of lesional cells were associated with HR 
HPV subtypes. P16 staining in  25% of cells was 
strongly associated with HPV negativity by ISH 
(p   0.0001).
Table 3 summarizes Ki-67 positivity in  50% of 
lesional cells in relation to H&E diagnosis and HPV 
ISH. Of the 34 Ki-67 positive cases, 27 (79.4%) were 
HR HPV positive while 7 cases (2 ASMs and 5 HG 
CINs) were HR HPV negative.
Followup (range: 1 to 19 months; mean: 7.4 
months; median: 6.0 months) for 50% (10) of the 
ASMs is shown in Table 4. Six of 8 cases that were 
p16/Ki-67 negative were negative on followup 
including one case that was HR HPV positive. 
One case that was p16/Ki-67/HR HPV negative 
showed LG CIN on followup and one case that 
was p16/Ki-67 negative showed ASM favored to 
be reactive on followup. Both of the p16 positive 
ASM cases that had followup were also HR HPV 
positive. One was Ki-67 positive, had HG CIN in 
a prior and concurrent biopsy, and ASCUS on 
followup while the other was Ki-67 negative, had 
LG CIN on a prior biopsy, and HG CIN on 
followup.
Discussion
In this study we have shown that p16/Ki-67 
Immunostaining is useful in stratiﬁ  cation of ASM 
into reactive and CIN groups by using the fol-
lowing criteria: (i) p16/Ki-67 negativity is 
indicative of a reactive change, (ii) band-like 
staining for p16 and Ki-67 positivity in  50% 
of lesional nuclei is indicative of HG CIN and 
Figure 3. (a) Atypical squamous metaplasia negative for (b) p16, (c) Ki-67, and (d) HPV consistent with reactive change.
Table 2A. P16 immunoreactivity and diagnosis 
(N = 100).
p16 Total HG CIN LG CIN Negative ASM
Band 33 24 4 0 5
S   75% 32 1 00
S25%–75% 5 0 2 2 1
S   25% 59 1 10 34 14
Table 2B. P16 immunoreactivity and HR HPV by ISH 
(N = 100).
p16 Total HR+ HR- HR ND
Band 33 25 8 0
S   75% 33 0 0
S25%–75% 5 1 3 1
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has a high correlation with HPV ISH positivity, 
(iii) p16 band positivity or spotty positivity 
in  75% of lesional cells by itself is suggestive 
of HPV infection, (iv) Ki-67 positive staining 
in  50% of nuclei with negative or spotty stain-
ing for p16 in  25% of lesional cells remains a 
nonspeciﬁ  c ﬁ  nding often observed in reactive 
epithelium. Our ﬁ  ndings are concordant with 
p16/Ki-67 immunostaining reported by others in 
cervical biopsies (Sano et al. 1998; Keating et al. 
2001; Klaes et al. 2001; Agoff et al. 2003; Hu 
et al. 2005; Duggan et al. 2006; O’Neill and 
McCluggage, 2006; Iaconis et al. 2007; Kong 
et al. 2007; Regauer and Rich, 2007) and by us 
in anal biopsies (Walts et al. 2006) and indicate 
that observations made in these epithelia can be 
applied to ASM. Seventy per cent of our cases 
with ASM could be reclassiﬁ  ed into reactive 
group or CIN. The remaining 30% showed 
equivocal staining results of which a third showed 
evidence of HPV infection by ISH.
Human papillomavirus (HPV) is the most 
common sexually transmitted infection in the 
United States with as many as 20 million persons 
infected (Torpy et al. 2007). The overall prevalence 
of infection is estimated at 26.8% in females 14 to 
59 years of age with the prevalence of high and 
low-risk HPV subtypes estimated at 15.2% and 
17.8%, respectively (Dunne et al. 2007). While 
HPV infection is very common, it is believed that 
up to 90% of infections clear spontaneously within 
2 years (Moscicki et al. 1998; Franco et al. 1999). 
Persistent infection by high-risk HPV subtypes has 
been shown to be the most consistent precursor to 
cervical carcinoma with HR HPV subtypes detect-
able in as many as 99% of cervical carcinomas 
(Walboomers et al. 1999).
Squamous metaplasia of the cervix is so 
common that it is virtually regarded as “normal”. 
Squamous metaplasia can be unifocal but is more 
frequently multifocal and almost always involves 
the transformation zone which is also involved in 
most CINs. Hence it is not surprising that ASM is 
a frequent diagnosis in surgical pathology. Often 
a tissue diagnosis of ASM is preceded by a 
cytological diagnosis of ASC-H (atypical squamous 
Table 3A. Ki-67 immunoreactivity and diagnosis (N = 100).
Ki-67 Total HG CIN LG CIN Negative ASM
Positive ( 50%) 34 24 6 0 4
Negative ( 50%) 66 3 11 36 16
Table 3B.  Ki-67 immunoreactivity and HR HPV by ISH (N = 100).
Ki-67 Total HR+ HR− HR ND
Positive ( 50%) 34 27 7 0
Negative ( 50%) 66 8 46 12
Table 4. Followup for ASMs (N = 10).
Initial proﬁ  le Followup
P16+/Ki−67+/HR+ Paps @ 5 and 14 months: ASCUS
P16+/Ki−67−/HR+ Cone @ 6 months: HG CIN
P16−/Ki−67−/HR ND LEEP @ 1 month: focal ASM (favor reactive)
P16−/Ki−67−/HR− Paps @ 3,7,11,15, and 19 months: all negative
P16−/Ki−67−/HR− Hysterectomy @ 5 months: negative 
P16−/Ki−67−/HR− Pap @ 6 months: negative
P16−/Ki−67−/HR− Hysterectomy @ 8 months: negative
P16−/Ki−67−/HR− Cone @ 6 months: LG CIN
P16−/Ki−67−/HR+ Pap @ 7 months: negative
P16−/Ki−67−/HR− Hysterectomy @ 2 months: negative41
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cells of undetermined signiﬁ  cance, cannot exclude 
high grade squamous intraepithelial lesion)(Solomon 
et al. 2002) which according to current clinical 
guidelines is an indication for colposcopy and 
biopsy without reﬂ  ex HPV (Wright et al. 2002) 
thus contributing to the expectation that biopsy 
will provide a deﬁ  nitive diagnosis upon which 
appropriate patient management can be based. 
While a biopsy diagnosis of CIN in metaplastic 
epithelium is an indication for cervical LEEP (loop 
electrosurgical excision procedure) or conization 
and a diagnosis of squamous metaplasia with reac-
tive cellular changes would not elicit further 
evaluation, a diagnosis of ASM not otherwise 
speciﬁ  ed presents gynecologists with a dilemma 
in patient management. Because the difference in 
management is great, there is a need for patholo-
gists to be able to reliably stratify ASM as reactive 
or CIN and to minimize the use of ASM as a diag-
nosis. Our ﬁ  ndings indicate that p16/Ki-67 immu-
nostains can be applied toward this end.
In our study cohort, the majority of biopsies 
that had been reported as ASM were p16/HPV 
negative suggesting that the atypia in these 
epithelia is reactive rather than CIN. Review of 
the literature indicates that regardless of whether 
immunostains, ISH, PCR, or followup is used as 
the gold standard for HPV, the tendency to 
“overdiagnose” squamous metaplasia as ASM is 
not unique to our laboratory. In a study utilizing 
CK17, p16, and p63 immunostains to distinguish 
atypical immature squamous metaplasia from HG 
CIN, Regauer (Regauer and Rich, 2007) reported 
that 59% (10 of the 17 cases that were reclassiﬁ  ed 
as benign. In another study of cervical biopsies 
utilizing clinical followup data, Duggan (Duggan 
et al. 2006) found that among 32 ASMs for which 
they had followup, the followup was benign in 
34.4% of cases and among the 21 that developed 
CIN, only 5 (24%) were HG CINs. Kong (Kong 
et al. 2007) in a study utilizing PCR found that 
14 (53.8%) of 26 biopsies reported as ASM were 
negative for HPV by PCR while in another study 
Keating (Keating et al. 2001) found that of 
12 ASMs, 50% were negative for HPV by PCR. 
While it should be acknowledged that each of 
these methodologies has its limitations as the 
“gold standard” for CIN, these reports attest to the 
necessity for pathologists to hone the use of ASM 
as a diagnosis.
To date, we are aware of few other studies 
(Keating et al. 2001; Duggan et al. 2006; Iaconis 
et al. 2007; Kong et al. 2007; Regauer and Rich, 
2007) that have speciﬁ  cally addressed p16/Ki-67 
immunostaining in ASM of the cervix. Differ-
ences in case selection, antibody clones, staining 
conditions, deﬁ  nitions of “positive” immunostain-
ing, biomarkers studied separately and in combi-
nation with p16 and/or Ki-67, and use of PCR vs. 
ISH as the “gold standard” for HPV, limit com-
parisons between these studies. In general, all 
workers found that overexpression of p16 (be it 
“band-like” staining for us or “diffuse strong 
positivity” for others) is strongly associated with 
HR HPV positivity (whether assayed by ISH or 
PCR) while focal or negative p16 staining is 
characteristic of LG CIN or reactive atypia. Dug-
gan (Duggan et al. 2006) concluded that “p16 
positivity and Ki-67 high index correlates with 
HG CIN and … the combination is useful in 
stratiﬁ  cation of some ASMs as HG CIN”. Iaconis 
(Iaconis et al.) also reported that the combination 
of p16 and Ki-67 immunostains is helpful in 
decreasing the number of atypical immature 
squamous metaplasia cases with “nondiagnostic 
atypia”. Keating (Keating et al. 2001) noted that 
Ki-67 positivity can be seen in the upper two-
thirds of BSM epithelium that is tangentially 
sectioned and/or inﬂ  amed and that Ki-67 by itself 
has a low speciﬁ  city as a biomarker for HPV. They 
also noted that “the association of p16 staining 
and HR HPV was not absolute” and suggest that 
not all HPV subtypes currently classiﬁ  ed as “HR” 
have the same ability for p16 upregulation. In 
their study using PCR, they comment that “HPV 
DNA sequences are not always identiﬁ  ed/con-
ﬁ  rmed in histological sections” that showed a 
“morphologic abnormality”. In this regard, it 
should be noted that a negative HPV ISH can 
occur in the presence of an HPV subtype that was 
not tested for (ISH probes we utilized only test 
for two LR and 12 HR subtypes) or when the HPV 
DNA present is below the detection threshold of 
the assay employed. Each study acknowledges 
the limitations in sensitivity and speciﬁ  city of any 
single biomarker and emphasizes the beneﬁ  t of 
utilizing a combination of biomarkers for optimal 
resolution of problematic biopsies. In our study, 
addition of Ki-67 positivity in  50% of lesional 
cells to p16 band positivity as diagnostic requi-
sites increased the speciﬁ  city (from 92.5% to 
96%) and the positive predictive value (from 
85.7% to 91.7%) for a diagnosis of HG CIN 
(Table 5).42
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